Jaguar Health Inc. (NASDAQ:JAGX) does about 5.39M shares in volume on a normal day but saw 4732473 shares change hands in Monday trading. The company now has a market cap of 16.18M USD and an enterprise value of about $23.33M. Its current market price is $0.40, marking an increase of 1.73% compared to the previous close of $0.39. The 52 week high reached by this stock is $1.60 whilst the lowest price level in 52 weeks is $0.35. The script in recent trading has seen the stock touch a high of $0.423 and a low of $0.38.

Jaguar Health Inc. (JAGX) has a 20-day trading average at $0.5562 and the current price is -75.00% off the 52-week high compared with 14.04% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.5925 and its 200-day simple moving average is $0.5879. If we look at the stock’s price movements over the week, volatility stands at 11.09%, which decreases to 10.67% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 35.52 to suggest the stock is neutral.

FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 11, 2017 when Rodman & Renshaw initiated the stock to “Buy” and issued a price target of $2.

The current price level is -29.85%, -32.81%, and -32.33% away from its SMA20, SMA50, and SMA200 respectively, with the JAGX price moving above the 50-day SMA on August 31. Jaguar Health Inc. (JAGX) stock is up 1.78% over the week and -38.82% over the past month. Its price is -50.06% year-to-date and -65.52% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.29 below consensus estimates by -$0.14. The company’s next earnings report is expected on 11/12/2020, with forecasts estimating quarterly EPS at -$0.14 and -$0.66 for whole year. JAGX’s earnings per share are forecast to grow by 92.70% this year and 31.80% over next year. Expected sales for next quarter are $6.29 million, which analysts say will come at $19.1 million for the current fiscal year and next year at $15.91 million. In addition, estimates put the company’s current quarterly revenue at an average of $5.82 million.

Its 12-month price target is $5.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.00.

Outstanding shares total 40.27M with insiders holding 10.37% of the shares and institutional holders owning 6.21% of the company’s common stock. The company has a return on investment of -208.00% and return on equity of -609.60%. The beta has a value of 0.77. Price to book ratio is 13.33 and price to sales ratio is 2.49.

According to a U.S. Securities and Exchange Commission filing, Keystone Investment Trust Plc has reduced its position in Jaguar Health Inc. (JAGX) to 236,530 shares, mirroring a recent drop by 0.00%. Keystone Investment Trust Plc dumped 0.0 shares of Jaguar Health Inc. common stock bringing its total worth to about $0.15 million at the end of recent close, SEC documents show. Keystone Investment Trust Plc isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 30,283 shares worth $19805.0. Invesco UK 2 Invt Series – UK St cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.08% position in Jaguar Health Inc. thanks to 25604.0 shares amounting to $16745.0.